Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth-Reference-Cited by-同舟云学术

Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

Published:2021-06-24 Issue:10 Volume:17 Page:1065-1074
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Lee Bianca J.,Boyer Jacob A.,Burnett G. Leslie^ORCID,Thottumkara Arun P.,Tibrewal Nidhi,Wilson Stacy L.,Hsieh Tientien,Marquez Abby,Lorenzana Edward G.,Evans James W.,Hulea Laura^ORCID,Kiss Gert,Liu Hui,Lee Dong,Larsson Ola^ORCID,McLaughlan Shannon,Topisirovic Ivan,Wang Zhengping,Wang Zhican,Zhao Yongyuan,Wildes David,Aggen James B.,Singh Mallika,Gill Adrian L.,Smith Jacqueline A. M.^ORCID,Rosen Neal^ORCID

Funder

Breast Cancer Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

https://www.nature.com/articles/s41589-021-00813-7.pdf

Reference56 articles.

1. Chalhoub, N. & Baker, S. J. PTEN and the PI3-kinase pathway in cancer. Annu Rev. Pathol. 4, 127–150 (2009).

2. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489–501 (2002).

3. Sarbassov, D. D. et al. RICTOR, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296–1302 (2004).